CD1d–invariant Natural Killer T cell axis (CD1d–iNKT axis)

The CD1d–invariant Natural Killer T (iNKT) cell axis is a specialized immunological pathway that bridges innate and adaptive immunity by facilitating the recognition of lipid antigens (PMID: 17205077). CD1d is a non-polymorphic, MHC class I-like glycoprotein that presents endogenous and exogenous glycolipids to the semi-invariant T-cell receptor (TCR) found on iNKT cells (UniProt: P15813). Upon activation, iNKT cells rapidly secrete a diverse array of cytokines, such as IFN-gamma and IL-4, which subsequently activate other immune effectors including dendritic cells, natural killer cells, and cytotoxic T lymphocytes (PMID: 24037302). This axis is a prominent therapeutic target in oncology, where synthetic agonists like alpha-galactosylceramide (alpha-GalCer) are employed to induce potent anti-tumor responses (PMID: 11257135). Additionally, the pathway plays significant roles in the pathogenesis and potential treatment of autoimmune diseases, asthma, and various infections (PMID: 18490738). Clinical challenges associated with targeting this axis include the induction of iNKT cell anergy and the risk of systemic cytokine release syndrome (PMID: 12414804).

Other names

CD1d-restricted iNKT cell pathwayCD1d-iNKT cell interactionCD1d-mediated lipid antigen presentationCD1d-iNKT axis

Agonism of the invariant T-cell receptor (iNKT TCR) through the presentation of glycolipid antigens by the CD1d molecule, resulting in rapid cytokine secretion and downstream activation of the innate and adaptive immune systems.